Cervical Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes

DelveInsight's "Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Cervical Cancer, historical and forecasted epidemiology as well as the Cervical Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cervical Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cervical Cancer Market Forecast
https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Cervical Cancer Market Report:
• The Cervical Cancer market size was valued ~USD 930 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, Zai Lab, a Chinese-American biopharmaceutical company, has announced positive topline results from the China-specific arm of its Phase III innovaTV-301 study evaluating its antibody-drug conjugate (ADC) TIVDAK (tisotumab vedotin). According to the results from the Chinese subpopulation, cervical cancer patients treated with TIVDAK experienced a 45% reduction in the risk of death compared to those receiving chemotherapy. The study enrolled patients with recurrent or metastatic cervical cancer who had previously undergone standard systemic therapies. While the median overall survival (OS)-the primary endpoint of the Phase III trial (NCT04697628)-was 10.7 months for chemotherapy, it had not yet been reached for the TIVDAK arm.
• In November 2024, Novotech, a global full-service clinical Contract Research Organization (CRO), has published a new report titled Cervical Cancer - Global Clinical Trial Landscape. The report provides an in-depth analysis of the global cervical cancer research landscape, emphasizing the critical role of clinical trials in improving treatment options. It covers key geographic trends, emerging therapies, and future projections, offering valuable insights for researchers and healthcare professionals dedicated to addressing this disease.
• The United States accounted for the highest Cervical Cancer market size valued ~USD 530 million in 2023
• In January 2024, Merck reported that the US Food and Drug Administration (FDA) has approved KEYTRUDA in combination with chemoradiotherapy (CRT) for treating patients diagnosed with FIGO 2014 Stage III-IVA cervical cancer. This approval is grounded in findings from the Phase III KEYNOTE-A18 trial.
• In 2023, the U.S. held the largest share of the cervical cancer market, valued at approximately USD 530 million.
• The American Cancer Society estimates that around 13,400 new cases of invasive cervical cancer will be diagnosed in the United States in 2025.
• According to Cooley et al. (2023), nearly 17.4% of patients in the U.S. were aged 65 or older. Among these older women, 71% were diagnosed with late-stage disease (stages II-IV), compared to 48% of women under 65. Additionally, the 5-year relative survival for late-stage disease was lower in women aged 65 and above (23.2-36.8%) than in those younger than 65 (41.5-51.5%).
• According to the Robert Koch Institute (2023), approximately 4,500 women were diagnosed with cervical cancer in Germany in 2022. The decreasing incidence of new invasive cervical cancer cases over the past decade continues a trend that began with a significant decline during the three decades before the 2000s. Before 2010, the incidence rates remained relatively stable.
• As reported by the European Cancer Information System (2022), Germany had around 4,544 cervical cancer cases, France reported approximately 3,185, Italy recorded about 2,479, Spain had roughly 2,020, and the UK documented close to 3,235 cases.
• In 2024, the total incident cervical cancer population in the 7MM exceeded 40,000 cases, with numbers projected to decline at a moderate CAGR by 2034.
• In the U.S., approximately 64% of cervical cancer cases are diagnosed as squamous carcinoma, 21% as adenocarcinoma, with the remaining cases classified as other types.
• In the U.S., cervical cancer is most frequently diagnosed at Stage IB, accounting for roughly 27% of cases, followed by Stage IVB as the next most common stage at diagnosis.
• Key Cervical Cancer Companies: AstraZeneca, Precigen, Transgene, Merck KGaA, Orano Med LLC, Hookipa Biotech GmbH, Gilead Sciences, MacroGenics, Genentech, Inc., Precision Biologics, Inc, Agenus Inc., Hoffmann-La Roche, Nurix Therapeutics, Inc., Iovance Biotherapeutics, Inc., Sensei Biotherapeutics, Inc., AstraZeneca, Daiichi Sankyo Co., Ltd., Verastem, Inc., CRISPR Therapeutics, Advenchen Laboratories, LLC, and others
• Key Cervical Cancer Therapies: Volrustomig, PRGN-2009, TG4001, 212Pb-DOTAMGRPR1, HB-201 IT, Sacituzumab govitecan, MGD019, Atezolizumab, NEO-201 in combination with pembrolizumab, AGEN2034, Tiragolumab + Atezolizumab, De-TIL-0255, LN-145 + pembrolizumab, SNS-101 (anti-VISTA), Trastuzumab deruxtecan, Avutometinib (VS-6766) + defactinib, CTX131, AL3818, and others
• The Cervical Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cervical Cancer pipeline products will significantly revolutionize the Cervical Cancer market dynamics.

Cervical Cancer Overview
Cervical cancer is a type of cancer that begins in the cells of the cervix, the lower part of the uterus (womb) that connects to the vagina. It is most often caused by persistent infection with certain strains of human papillomavirus (HPV), a sexually transmitted virus. Early-stage cervical cancer may not cause noticeable symptoms, but advanced stages can lead to abnormal vaginal bleeding, pelvic pain, and pain during intercourse. Regular screening through Pap smears or HPV tests can help detect precancerous changes or early cancer, which can be treated more effectively. Treatment options include surgery, radiation, and chemotherapy, depending on the cancer's stage. Vaccination against HPV can help prevent cervical cancer.

Get a Free sample for the Cervical Cancer Market Report:
https://www.delveinsight.com/report-store/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cervical Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cervical Cancer Epidemiology Segmentation:
The Cervical Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Incident Cases of Cervical Cancer in the US
• Stage-specific Incident Cases of Cervical Cancer in the US
• Histological type-specific Incident Cases of Cervical Cancer in the US
• Age-specific Incident Cases of Cervical Cancer in the US

Download the report to understand which factors are driving Cervical Cancer epidemiology trends @ Cervical Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cervical Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cervical Cancer market or expected to get launched during the study period. The analysis covers Cervical Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cervical Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cervical Cancer Therapies and Key Companies
• Volrustomig: AstraZeneca
• PRGN-2009: Precigen
• TG4001: Transgene/Merck KGaA
• 212Pb-DOTAMGRPR1: Orano Med LLC
• HB-201 IT: Hookipa Biotech GmbH
• Sacituzumab govitecan: Gilead Sciences
• MGD019: MacroGenics
• Atezolizumab: Genentech, Inc.
• NEO-201 in combination with pembrolizumab: Precision Biologics, Inc
• AGEN2034: Agenus Inc.
• Tiragolumab + Atezolizumab: Hoffmann-La Roche
• De-TIL-0255: Nurix Therapeutics, Inc.
• LN-145 + pembrolizumab: Iovance Biotherapeutics, Inc.
• SNS-101 (anti-VISTA): Sensei Biotherapeutics, Inc.
• Trastuzumab deruxtecan: AstraZeneca/Daiichi Sankyo Co., Ltd.
• Avutometinib (VS-6766) + defactinib: Verastem, Inc.
• CTX131: CRISPR Therapeutics
• AL3818: Advenchen Laboratories, LLC

Discover more about therapies set to grab major Cervical Cancer market share @ Cervical Cancer Treatment Market
https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cervical Cancer Market Strengths
• Introduction of immunotherapies such as KEYTRUDA and LIBTAYO, enhancing early diagnosis and treatment, significantly enhanced survival rates in cervical cancer.
• In the United States, KEYTRUDA stands as the sole approved immunotherapy agent for PD-L1(+) cervical cancers and cervical cancers with a tumor mutational burden of 10 or higher.

Cervical Cancer Market Opportunities
• New therapies for r/mCC should offer substantial clinical advantages while avoiding excessive healthcare resource utilization. Further investigation is crucial to grasp how treatment approaches for r/mCC correlate with subsequent clinical results.
• Immunotherapy presents an opportunity to set new standards of care for treating cervical cancers. The identification of biomarkers to evaluate response to immunotherapy is also expected to play a crucial role in identifying optimal candidates for treatment.

Scope of the Cervical Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cervical Cancer Companies: AstraZeneca, Precigen, Transgene, Merck KGaA, Orano Med LLC, Hookipa Biotech GmbH, Gilead Sciences, MacroGenics, Genentech, Inc., Precision Biologics, Inc, Agenus Inc., Hoffmann-La Roche, Nurix Therapeutics, Inc., Iovance Biotherapeutics, Inc., Sensei Biotherapeutics, Inc., AstraZeneca, Daiichi Sankyo Co., Ltd., Verastem, Inc., CRISPR Therapeutics, Advenchen Laboratories, LLC, and others
• Key Cervical Cancer Therapies: Volrustomig, PRGN-2009, TG4001, 212Pb-DOTAMGRPR1, HB-201 IT, Sacituzumab govitecan, MGD019, Atezolizumab, NEO-201 in combination with pembrolizumab, AGEN2034, Tiragolumab + Atezolizumab, De-TIL-0255, LN-145 + pembrolizumab, SNS-101 (anti-VISTA), Trastuzumab deruxtecan, Avutometinib (VS-6766) + defactinib, CTX131, AL3818, and others
• Cervical Cancer Therapeutic Assessment: Cervical Cancer current marketed and Cervical Cancer emerging therapies
• Cervical Cancer Market Dynamics: Cervical Cancer market drivers and Cervical Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cervical Cancer Unmet Needs, KOL's views, Analyst's views, Cervical Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.